SCARTOZZI, MARIO
SCARTOZZI, MARIO
DIPARTIMENTO DI SCIENZE MEDICHE E SANITA' PUBBLICA
5-Fluorouracil (5FU) is beneficial in patients with metastatic colorectal cancer progressing after 5FU-based first line chemotherapy.
2004-01-01 Berardi, R; Scartozzi, Mario; Labianca, R; Sobrero, A; Catalano, G; Catalano, V; Graziano, F; Barni, S; Zaniboni, A; Beretta, Gd; Cascinu, S.
5-fluorouracil pharmacogenomics: still rocking after all these years?
2011-01-01 Scartozzi, Mario; Maccaroni, E; Giampieri, R; Pistelli, M; Bittoni, A; Del Prete, M; Berardi, R; Cascinu, S.
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation
2008-01-01 Cascinu, S; Berardi, R; Salvagni, S; Beretta, Gd; Catalano, V; Pucci, F; Sobrero, A; Tagliaferri, P; Labianca, R; Scartozzi, Mario; Crocicchio, F; Mari, E; Ardizzoni, A.
A cost-benefit analysis of chemotherapy for gastric cancer
2004-01-01 Galizia, E; Berardi, R; Scartozzi, Mario; Cascinu, S.
A narrative review of the principal glucocorticoids employed in cancer
2022-01-01 Denaro, Nerina; Garrone, Ornella; Morelli, Annamaria; Pellegrino, Benedetta; Merlano, Marco Carlo; Vacca, Denise; Pearce, Josie; Farci, Daniele; Musolino, Antonino; Scartozzi, Mario; Tommasi, Chiara; Solinas, Cinzia
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index
2021-01-01 Rovesti, G.; Leone, F.; Brandi, G.; Cesario, S.; Scartozzi, M.; Niger, M.; Yoo, C.; Filippi, R.; Casagrande, M.; Silvestris, N.; Santini, D.; Faloppi, L.; Palloni, A.; Aglietta, M.; Bernardini, L.; Cho, H.; Lai, E.; Fenocchio, E.; Pircher, C.; Iacono, D.; De Lorenzo, S.; Sperti, E.; Massa, V.; De Braud, F.; Jeong, J. H.; Aprile, G.; Burgio, V.; Cascinu, S.; Casadei-Gardini, A.
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy
2021-01-01 Filippi, R.; Montagnani, F.; Lombardi, P.; Fornaro, L.; Aprile, G.; Casadei-Gardini, A.; Faloppi, L.; Palloni, A.; Satolli, M. A.; Scartozzi, M.; Citarella, F.; Lutrino, S. E.; Vivaldi, C.; Silvestris, N.; Rovesti, G.; Rimini, M.; Aglietta, M.; Brandi, G.; Leone, F.
A review of immune checkpoint blockade in breast cancer
2021-01-01 Pellegrino, B.; Tommasi, C.; Cursio, O. E.; Musolino, A.; Migliori, E.; De Silva, P.; Senevirathne, T. H.; Schena, M.; Scartozzi, M.; Farci, D.; Willard-Gallo, K.; Solinas, C.
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study
2019-01-01 Loupakis, Fotios; Intini, Rossana; Cremolini, Chiara; Orlandi, Armando; Sartore-Bianchi, Andrea; Pietrantonio, Filippo; Pella, Nicoletta; Spallanzani, Andrea; Dell'Aquila, Emanuela; Scartozzi, Mario; De Luca, Emmanuele; Rimassa, Lorenza; Formica, Vincenzo; Leone, Francesco; Calvetti, Lorenzo; Aprile, Giuseppe; Antonuzzo, Lorenzo; Urbano, Federica; Prenen, Hans; Negri, Francesca; Di Donato, Samantha; Buonandi, Pasquale; Tomasello, Gianluca; Avallone, Antonio; Zustovich, Fable; Moretto, Roberto; Antoniotti, Carlotta; Salvatore, Lisa; Calegari, Maria Alessandra; Siena, Salvatore; Morano, Federica; Ongaro, Elena; Cascinu, Stefano; Santini, Daniele; Ziranu, Pina; Schirripa, Marta; Buggin, Federica; Prete, Alessandra Anna; Depetris, Ilaria; Biason, Paola; Lonardi, Sara; Zagonel, Vittorina; Fassan, Matteo; Di Maio, Massimo
A19 CLINICAL FACTORS INFLUENCING GLOBAL OUTCOME IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS RECEIVING SECOND AND THIRD LINE TREATMENTS.
2009-01-01 Mazzanti, P; Scartozzi, Mario; Giampieri, R; Gasparini, S; Zuccatosta, L; Berardi, R; Cascinu, S.
Acetylsalicylic acid as a neo-adjuvant agent during preoperative chemoradiation for rectal cancer
2015-01-01 Restivo, Angelo; Cabras, Francesco; Cocco, F; Scartozzi, Mario; Zorcolo, Luigi
Activated NF-kappa B in colorectal cancer: Predictive or prognostic factor? Reply
2008-01-01 Scartozzi, Mario; Berardi, R; Cascinu, S; Bearzi, I; Mandolesi, A.
Activated NF-kB in colorectal cancer: predictive or prognostic factor?
2007-01-01 Scartozzi, Mario; Berardi, R; Cascinu, S; Mandolesi, A; Bearzi, I.
Adenocarcinoma Arising from Ileoanal J-pouch Mucosa: An Announced Event?
2011-01-01 Marmorale, C; Stortoni, P; Siquini, W; Scartozzi, Mario; Berardi, R; Mandolesi, A; Bearzi, I; Fianchini, A.
Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
2023-01-01 Petrelli, Fausto; Bertaglia, Valentina; Parati, Maria Chiara; Borgonovo, Karen; De Silva, Pushpamali; Luciani, Andrea; Novello, Silvia; Scartozzi, Mario; Emens, Leisha A; Solinas, Cinzia
Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature.
2003-01-01 Berardi, R; Scartozzi, Mario; Galizia, E; Cascinu, S.
Adjuvant treatment after surgical resection
2012-01-01 Scartozzi, Mario; Siquini, W; Maccaroni, E; Bianconi, M; Giampieri, R; Cascinu, S.
Adjuvant treatment for radically resected gastric cancer patients: The vexata quaestio
2008-01-01 Galizia, Eva; Scartozzi, Mario; Berardi, Rossana; Pistelli, Mirco; Bittoni, Alessandro; Cascinu, Stefano
Aflibercept, a new way to target angiogenesis in the second line treatment of metastatic colorectal cancer (mCRC)
2016-01-01 Scartozzi, Mario; Vincent, Loic; Chiron, Marielle; Cascinu, Stefano
Agenti antimetastatici.
2005-01-01 Berardi, R; Scartozzi, Mario; Cascinu, S.
Titolo | Data di pubblicazione | Autore(i) | Rivista | Editore |
---|---|---|---|---|
5-Fluorouracil (5FU) is beneficial in patients with metastatic colorectal cancer progressing after 5FU-based first line chemotherapy. | 1-gen-2004 | Berardi, R; Scartozzi, Mario; Labianca, R; Sobrero, A; Catalano, G; Catalano, V; Graziano, F; Barni, S; Zaniboni, A; Beretta, Gd; Cascinu, S. | JOURNAL OF CLINICAL ONCOLOGY | - |
5-fluorouracil pharmacogenomics: still rocking after all these years? | 1-gen-2011 | Scartozzi, Mario; Maccaroni, E; Giampieri, R; Pistelli, M; Bittoni, A; Del Prete, M; Berardi, R; Cascinu, S. | PHARMACOGENOMICS | - |
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation | 1-gen-2008 | Cascinu, S; Berardi, R; Salvagni, S; Beretta, Gd; Catalano, V; Pucci, F; Sobrero, A; Tagliaferri, P; Labianca, R; Scartozzi, Mario; Crocicchio, F; Mari, E; Ardizzoni, A. | BRITISH JOURNAL OF CANCER | - |
A cost-benefit analysis of chemotherapy for gastric cancer | 1-gen-2004 | Galizia, E; Berardi, R; Scartozzi, Mario; Cascinu, S. | EXPERT OPINION ON PHARMACOTHERAPY | - |
A narrative review of the principal glucocorticoids employed in cancer | 1-gen-2022 | Denaro, Nerina; Garrone, Ornella; Morelli, Annamaria; Pellegrino, Benedetta; Merlano, Marco Carlo; Vacca, Denise; Pearce, Josie; Farci, Daniele; Musolino, Antonino; Scartozzi, Mario; Tommasi, Chiara; Solinas, Cinzia | SEMINARS IN ONCOLOGY | - |
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index | 1-gen-2021 | Rovesti, G.; Leone, F.; Brandi, G.; Cesario, S.; Scartozzi, M.; Niger, M.; Yoo, C.; Filippi, R.; Casagrande, M.; Silvestris, N.; Santini, D.; Faloppi, L.; Palloni, A.; Aglietta, M.; Bernardini, L.; Cho, H.; Lai, E.; Fenocchio, E.; Pircher, C.; Iacono, D.; De Lorenzo, S.; Sperti, E.; Massa, V.; De Braud, F.; Jeong, J. H.; Aprile, G.; Burgio, V.; Cascinu, S.; Casadei-Gardini, A. | JOURNAL OF GASTROINTESTINAL CANCER | - |
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy | 1-gen-2021 | Filippi, R.; Montagnani, F.; Lombardi, P.; Fornaro, L.; Aprile, G.; Casadei-Gardini, A.; Faloppi, L.; Palloni, A.; Satolli, M. A.; Scartozzi, M.; Citarella, F.; Lutrino, S. E.; Vivaldi, C.; Silvestris, N.; Rovesti, G.; Rimini, M.; Aglietta, M.; Brandi, G.; Leone, F. | ACTA ONCOLOGICA | - |
A review of immune checkpoint blockade in breast cancer | 1-gen-2021 | Pellegrino, B.; Tommasi, C.; Cursio, O. E.; Musolino, A.; Migliori, E.; De Silva, P.; Senevirathne, T. H.; Schena, M.; Scartozzi, M.; Farci, D.; Willard-Gallo, K.; Solinas, C. | SEMINARS IN ONCOLOGY | - |
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study | 1-gen-2019 | Loupakis, Fotios; Intini, Rossana; Cremolini, Chiara; Orlandi, Armando; Sartore-Bianchi, Andrea; Pietrantonio, Filippo; Pella, Nicoletta; Spallanzani, Andrea; Dell'Aquila, Emanuela; Scartozzi, Mario; De Luca, Emmanuele; Rimassa, Lorenza; Formica, Vincenzo; Leone, Francesco; Calvetti, Lorenzo; Aprile, Giuseppe; Antonuzzo, Lorenzo; Urbano, Federica; Prenen, Hans; Negri, Francesca; Di Donato, Samantha; Buonandi, Pasquale; Tomasello, Gianluca; Avallone, Antonio; Zustovich, Fable; Moretto, Roberto; Antoniotti, Carlotta; Salvatore, Lisa; Calegari, Maria Alessandra; Siena, Salvatore; Morano, Federica; Ongaro, Elena; Cascinu, Stefano; Santini, Daniele; Ziranu, Pina; Schirripa, Marta; Buggin, Federica; Prete, Alessandra Anna; Depetris, Ilaria; Biason, Paola; Lonardi, Sara; Zagonel, Vittorina; Fassan, Matteo; Di Maio, Massimo | EUROPEAN JOURNAL OF CANCER | - |
A19 CLINICAL FACTORS INFLUENCING GLOBAL OUTCOME IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS RECEIVING SECOND AND THIRD LINE TREATMENTS. | 1-gen-2009 | Mazzanti, P; Scartozzi, Mario; Giampieri, R; Gasparini, S; Zuccatosta, L; Berardi, R; Cascinu, S. | ANNALS OF ONCOLOGY | - |
Acetylsalicylic acid as a neo-adjuvant agent during preoperative chemoradiation for rectal cancer | 1-gen-2015 | Restivo, Angelo; Cabras, Francesco; Cocco, F; Scartozzi, Mario; Zorcolo, Luigi | EUROPEAN JOURNAL OF CANCER | - |
Activated NF-kappa B in colorectal cancer: Predictive or prognostic factor? Reply | 1-gen-2008 | Scartozzi, Mario; Berardi, R; Cascinu, S; Bearzi, I; Mandolesi, A. | JOURNAL OF CLINICAL ONCOLOGY | - |
Activated NF-kB in colorectal cancer: predictive or prognostic factor? | 1-gen-2007 | Scartozzi, Mario; Berardi, R; Cascinu, S; Mandolesi, A; Bearzi, I. | JOURNAL OF CLINICAL ONCOLOGY | - |
Adenocarcinoma Arising from Ileoanal J-pouch Mucosa: An Announced Event? | 1-gen-2011 | Marmorale, C; Stortoni, P; Siquini, W; Scartozzi, Mario; Berardi, R; Mandolesi, A; Bearzi, I; Fianchini, A. | INFLAMMATORY BOWEL DISEASES | - |
Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis | 1-gen-2023 | Petrelli, Fausto; Bertaglia, Valentina; Parati, Maria Chiara; Borgonovo, Karen; De Silva, Pushpamali; Luciani, Andrea; Novello, Silvia; Scartozzi, Mario; Emens, Leisha A; Solinas, Cinzia | BREAST | - |
Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature. | 1-gen-2003 | Berardi, R; Scartozzi, Mario; Galizia, E; Cascinu, S. | I SUPPLEMENTI DI TUMORI | - |
Adjuvant treatment after surgical resection | 1-gen-2012 | Scartozzi, Mario; Siquini, W; Maccaroni, E; Bianconi, M; Giampieri, R; Cascinu, S. | - | - |
Adjuvant treatment for radically resected gastric cancer patients: The vexata quaestio | 1-gen-2008 | Galizia, Eva; Scartozzi, Mario; Berardi, Rossana; Pistelli, Mirco; Bittoni, Alessandro; Cascinu, Stefano | ADVANCES IN GASTROINTESTINAL CANCERS | - |
Aflibercept, a new way to target angiogenesis in the second line treatment of metastatic colorectal cancer (mCRC) | 1-gen-2016 | Scartozzi, Mario; Vincent, Loic; Chiron, Marielle; Cascinu, Stefano | TARGETED ONCOLOGY | - |
Agenti antimetastatici. | 1-gen-2005 | Berardi, R; Scartozzi, Mario; Cascinu, S. | - | - |